Search results
Showing 166 to 180 of 1001 results for public health medicine & health
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
In development Reference number: GID-TA10143 Expected publication date: TBC
In development Reference number: GID-TA11186 Expected publication date: TBC
This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.
Find out more about NICE technology appraisals advisory committee D members
Find out more about NICE technology appraisals advisory committee D members
Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)
This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS96Show all sections
Sections for QS96
- Quality statements
- Quality statement 1: Advice to support self-management
- Quality statement 2: Urgent endoscopy
- Quality statement 3: Testing conditions for Helicobacter pylori
- Quality statement 4: Discussion about referral for non-urgent endoscopy
- Quality statement 5: Referral to a specialist service
- Update information
- About this quality standard
In development Reference number: GID-TA11649 Expected publication date: 14 October 2026
In development Reference number: GID-TA11636 Expected publication date: 26 August 2026
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]
In development Reference number: GID-TA11096 Expected publication date: 03 September 2026
This guideline covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. The recommendations apply to bipolar I, bipolar II, mixed affective and rapid cycling disorders. It aims to improve access to treatment and quality of life in people with bipolar disorder.
In development Reference number: GID-TA11635 Expected publication date: 26 August 2026
This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under). It is relevant for mental health, health and community settings. The guideline aims to safeguard both staff and people who use services by helping to prevent violent situations and providing guidance to manage them safely when they occur.
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Initial education in adrenaline auto-injector use
- Quality statement 2: Referral to specialist allergy services after emergency treatment
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4: Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
Biographies for all current members of the diagnostics advisory committee.